Partner Article
Northwich’s Dechra Pharmaceuticals see group revenue increase by 12%
Northwich-based Dechra Pharmaceuticals, a manufacturer of veterinary products, has seen group revenue increase by 12%
This is due to group sales increasing by 59% in the USA, with sales in Europe increasing by 7%.
The group report that trading has been solid and finances remain in line with what was expected.
CEO, Ian Page, said: “The positive momentum experienced during the end of the last financial year has been maintained.
“On the strength of our recent revenue growth, we will accelerate investment in our sales and marketing infrastructure, particularly in the US as we look to strengthen our market presence.
“We remain confident that the execution of our strategy will continue to deliver future value.”
This was posted in Bdaily's Members' News section by Sophia Taha .
The real value of AI is the time it gives back
Breaking the magnetic pull of London
AI scepticism is healthy. Inaction isn't.
What does NPPF mean for site price and planning gain?
What new NPPF rules mean for landowners
The hidden cost squeezing Britain's economy
Teesside deserves more than cashback devolution
Construction must be built on commercial discipline
Devolution needs financial firepower to drive growth
The value of creating a stronger careers route
Apprenticeships: Invest in talent or keep chasing it
Are you ready for salary transparency?